Logo

American Heart Association

  18
  0


Final ID: MP1793

Prevalence and Recovery of Arrhythmia-Induced Cardiomyopathy in Patients with Newly Diagnosed Heart Failure Using a Wearable Defibrillator: A Real-World Cohort Study

Abstract Body (Do not enter title and authors here): Background:
Arrhythmia-induced cardiomyopathy (AIC) is a potentially reversible cause of heart failure triggered by sustained arrhythmias. Its true real-world prevalence and clinical recognition remain limited. This study aimed to assess the frequency, predictors, and outcomes of AIC in patients with newly diagnosed left ventricular systolic dysfunction (LVSD) and concurrent arrhythmia, undergoing rhythm control while protected by a wearable cardioverter-defibrillator (WCD).

Methods:
We analyzed 780 patients treated with a WCD between 2017 and 2023. Among them, patients with newly diagnosed idiopathic LVSD (LVEF <35%) and arrhythmias (atrial fibrillation, flutter, or ventricular ectopy >20%) were identified. Diagnostic workup included echocardiography, cardiac MRI, and ischemia testing or coronary angiography. Patients underwent rhythm control (cardioversion, antiarrhythmic drugs, and/or catheter ablation) and were followed up to 6 months. AIC was defined as LVEF improvement >15% in patients with restored sinus rhythm.

Results:
Among 780 patients treated with a WCD, 142 (18.2%) had first diagnosis of LVSD in the presence of arrhythmia (Figure 1). Of these, 68 (47.9%) had an identifiable etiology (Figure 2). The remaining 74 (52.1%) with idiopathic LVSD were analyzed. At mean follow-up of 133 days (4.5 months), 20 (27%) of 74 patients remained in arrhythmia (non-responders). Among 54 responders with restored sinus rhythm, 32 (59.3%) fulfilled AIC criteria; 22 (40.7%) were non-AIC. LVEF improved from 28% to 43% in AIC vs. 24% to 32% in non-AIC. Full recovery (LVEF >50%) was achieved in 56.3% of AIC patients during follow-up. Atrial fibrillation was most common (81.3% AIC vs. 95.5% non-AIC), followed by flutter; ventricular ectopy occurred in 9.4% of AIC cases. Heart failure therapy was comparable. Non-AIC patients showed larger LVEDD/LVESD, lower heart rates, more mitral regurgitation, and more frequent late gadolinium enhancement on MRI. No appropriate WCD shocks occurred. ICDs were implanted in 36.4% of non-AIC vs. 3.1% of AIC patients (p=0.001). No deaths were reported. LVEF <25% predicted lack of full recovery (p=0.04).

Conclusions:
AIC is a common and reversible form of LVSD in patients with arrhythmia and newly diagnosed idiopathic cardiomyopathy. Early rhythm control supported by WCD, combined with detailed diagnostics including cardiac MRI and ischemia testing, enables identification of reversible dysfunction and may reduce unnecessary ICD implantation.
  • Yogarajah, Joerg  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Hain, Andreas  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Dannenbaum, Jana  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Halim, Ahmed  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Mensch, Matthias  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Kuniss, Malte  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Neumann, Thomas  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Rieth, Andreas  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Treiber, Julia  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Sossalla, Samuel  ( Kerckhoff Heart Center , Frankfurt am Main , Germany )
  • Author Disclosures:
    Joerg Yogarajah: DO NOT have relevant financial relationships | Andreas Hain: DO have relevant financial relationships ; Speaker:Abbott:Active (exists now) ; Speaker:Zoll:Past (completed) ; Advisor:Biotronik:Active (exists now) | Jana Dannenbaum: No Answer | Ahmed Halim: No Answer | Matthias Mensch: No Answer | Malte Kuniss: No Answer | Thomas Neumann: DO NOT have relevant financial relationships | Andreas Rieth: DO have relevant financial relationships ; Speaker:AstraZeneca:Past (completed) ; Speaker:Corvia Medical:Past (completed) ; Speaker:Bayer:Active (exists now) | Julia Treiber: No Answer | Samuel Sossalla: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Innovations and Safety Considerations in Cardiac Implantable Electronic Devices

Sunday, 11/09/2025 , 03:15PM - 04:30PM

Moderated Digital Poster Session

More abstracts on this topic:
A Bridge from Sweet to Sour: A Case of Recurrent Myocardial Stunning in Diabetic Ketoacidosis

Satish Vikyath, Pargaonkar Sumant, Slipczuk Leandro, Schenone Aldo, Maliha Maisha, Chi Kuan Yu, Sunil Kumar Sriram, Borkowski Pawel, Vyas Rhea, Rodriguez Szaszdi David Jose Javier, Kharawala Amrin, Seo Jiyoung

A Case of Recurrent Acute Coronary Syndrome and Cardiogenic Shock due to Apolipoprotein A-IV Amyloidosis

Muthukkumar Rashmi, Holmes Taylor, Friede Kevin

More abstracts from these authors:
Efficacy and safety of Digitoxin in heart failure with reduced ejection fraction according to age: Insights from DIGIT-HF

Bavendiek Udo, Huelsmann Martin, Von Der Leyen Heiko, Veltmann Christian, Stork Stefan, Boehm Michael, Koch Armin, Bauersachs Johann, Berliner Dominik, Thomas Nele, Grosshennig Anika, Schwab Johannes, Rieth Andreas, Maier Lars, Gaspar Thomas, Zdravkovic Marija

You have to be authorized to contact abstract author. Please, Login
Not Available